What new FDA approvals did Trodelvy receive for first-line TNBC treatment?

The FDA approved Trodelvy (sacituzumab govitecan‑hziy) for two first‑line triple‑negative breast cancer indications: as monotherapy for patients ineligible for PD‑1/PD‑L1 therapy and in combination with pembrolizumab (Keytruda) for PD‑L1‑positive tumors. The decision was based on ASCENT‑03 and ASCENT‑04 trials showing improved progression‑free survival.